Merck beat earnings estimates in Q4 2025, raised 2026 guidance, and saw insider selling despite a "Moderate Buy" rating.

Merck & Co. reported strong Q4 2025 earnings on February 3, 2026, with $2.04 EPS and $16.4 billion in revenue, surpassing estimates, and raised its 2026 full-year EPS guidance to $5.00–$5.15. The stock closed at $121.39 on February 16, with a market cap of $301.29 billion and a 2.8% dividend yield. Institutional investors including Vanguard reduced stakes, while others like Texas Yale Capital and Pallas Capital increased holdings. Insiders sold 320,176 shares worth $38.3 million over 90 days. Analysts rate the stock a “Moderate Buy” with a $123.71 target.